DelveInsight’s “Systemic Mastocytosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Systemic Mastocytosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Systemic Mastocytosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Systemic Mastocytosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Systemic Mastocytosis: An Overview
According to the National Organization of Rare Diseases (NORD), Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. It is generally found in adults.
Mutations in the KIT gene mainly cause the disease. It has been seen that most cases are sporadic and not inherited, but familial cases rarely have been reported. Systemic mastocytosis can be divided into four main categories which are distinguished by various features: 1) Indolent systemic mastocytosis (ISM), 2) Systemic mastocytosis with an associated hematologic non-mast cell lineage disorder (SM-AHNMD), 3) Aggressive systemic mastocytosis (ASM), and 4) Mast cell leukemia (MCL).
Signs and symptoms of the disease vary based on which part of the body is affected but may include anemia and bleeding disorders, gastrointestinal symptoms, itching and/or flushing of the skin, anaphylactic reactions, enlarged liver (hepatomegaly), spleen (splenomegaly), and lymph nodes (lymphadenopathy). Mastocytosis, in all of its forms, is a rare disease and the exact incidence is unknown. Mastocytosis affects males and females in equal ratios.
Systemic Mastocytosis Market Key Facts
According to the National Institute of Health (NIH), systemic mastocytosis is estimated to occur in 1 per 10,000 to 20,000 individuals worldwide.
As per the study titled “Prevalence of indolent systemic mastocytosis in a Dutch region” by Doormaal J. et al. the prevalence of indolent systemic mastocytosis was reported as at least 13 per 100,000 inhabitants.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Systemic Mastocytosis pipeline therapies. It also thoroughly assesses the Systemic Mastocytosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Systemic Mastocytosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Systemic Mastocytosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Systemic Mastocytosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Systemic Mastocytosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Systemic Mastocytosis Epidemiology, Segmented as –
Prevalent Population of Systemic Mastocytosis (SM) (2019–2032)
Type-Specific Cases of Systemic Mastocytosis (SM) (2019–2032)
Diagnosed and Treatable Cases of Systemic Mastocytosis (SM) (2019–2032)
Systemic Mastocytosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Systemic Mastocytosis market or expected to be launched during the study period. The analysis covers the Systemic Mastocytosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Systemic Mastocytosis drugs based on their sale and market share.
The report also covers the Systemic Mastocytosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Systemic Mastocytosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Systemic Mastocytosis Market Will Evolve and Grow by 2032 @
Systemic Mastocytosis Therapeutics Analysis
The treatment algorithm for Systemic Mastocytosis (SM) includes several options such as cytoreductive treatments used for advanced SM (including 2-Chlorodeoxyadenosine (2-CDA) and IFN-α), classical chemotherapy agents (such as cytarabine or fludarabine), but all with modest and disappointing response rates, highlighting the need for innovative therapies. Once the disease is diagnosed, various treatment options are prescribed according to the type, severity, and symptoms of the disease.
The treatment regimen of Systemic Mastocytosis involves a multidisciplinary approach which involves a few expert physicians to create a patient’s overall treatment plan that combines different types of treatments. The most important parameter in treating Systemic Mastocytosis involves controlling the symptoms of the patient. Certain Cytoreductive therapies can be used which target IFN-α, and have been considered as the first-line treatment for patients with advanced mastocytosis for many years. One such product includes Cladribine (or 2-CdA), which is used as an off-label corticosteroid and has shown therapeutic activity in all SM subtypes, including MCL. Dasatinib (an off-label) multi-kinase inhibitor active against BCR-ABL1, KIT, and PDGFRa and has shown promising in vitro activity against various KIT mutants, including D816V, but generally, it is not recommended much by physicians.
Several major pharma and biotech companies are developing therapies for Systemic Mastocytosis. Currently, Blueprint Medicines is leading the therapeutic market with its Systemic Mastocytosis drug candidates in the most advanced stage of clinical development.
Systemic Mastocytosis Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Systemic Mastocytosis Therapies Covered in the Report Include:
Avapritinib: Blueprint Medicines
Masitinib: AB Sciences
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Systemic Mastocytosis Competitive Intelligence Analysis
4. Systemic Mastocytosis Market Overview at a Glance
5. Systemic Mastocytosis Disease Background and Overview
6. Systemic Mastocytosis Patient Journey
7. Systemic Mastocytosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Systemic Mastocytosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Mastocytosis Unmet Needs
10. Key Endpoints of Systemic Mastocytosis Treatment
11. Systemic Mastocytosis Marketed Therapies
12. Systemic Mastocytosis Emerging Drugs and Latest Therapeutic Advances
13. Systemic Mastocytosis Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Mastocytosis Market Outlook (In US, EU5, and Japan)
16. Systemic Mastocytosis Companies Active in the Market
17. Systemic Mastocytosis Access and Reimbursement Overview
18. KOL Views on the Systemic Mastocytosis Market
19. Systemic Mastocytosis Market Drivers
20. Systemic Mastocytosis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Renal Insufficiency Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Renal Insufficiency market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Renal Insufficiency market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States